361 related articles for article (PubMed ID: 23709210)
1. Natalizumab therapy for multiple sclerosis.
Derfuss T; Kuhle J; Lindberg R; Kappos L
Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
Bennett JL
Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
[TBL] [Abstract][Full Text] [Related]
7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
8. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
10. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Stüve O; Marra CM; Cravens PD; Singh MP; Hu W; Lovett-Racke A; Monson NL; Phillips JT; Tervaert JW; Nash RA; Hartung HP; Kieseier BC; Racke MM; Frohman EM; Hemmer B
Arch Neurol; 2007 Feb; 64(2):169-76. PubMed ID: 17296831
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
12. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
13. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
Gupta S; Weinstock-Guttman B
Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
[TBL] [Abstract][Full Text] [Related]
15. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
16. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
Takao M
Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
[TBL] [Abstract][Full Text] [Related]
17. Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
[TBL] [Abstract][Full Text] [Related]
18. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
19. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Landy DC; Hecht EM
Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
[TBL] [Abstract][Full Text] [Related]
20. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
